The finding that CD13 and/or CD33 positivity was correlated with BCR::ABL1, a well‐recognized treatment target in the tyrosine kinase inhibitor (TKI) regimen, prompted us to examine its prognostic value in B‐ALL in depth. Here, CD33 is linked to acute lymphoblastic leukemia.